"Funding - CYP is currently cash flow negative and will likely require additional capital to fund the development of CYP-001 and its other programs. "
Or p 66 of 67
Additional disclosures
"Euroz Hartleys declares that it has provided corporate advice during the last year and has received a fee for these services from: Cynata Therapeutics "
and
"may effect transactions not consistent with the recommendations (if any) in this report"
CYP Price at posting:
21.5¢ Sentiment: Sell Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)